Immunovant prices $550M stock offering; updates IMVT-1402 and batoclimab timelines

Immunovant, Inc.

Underwritten common stock offering of ~$550M gross proceeds; Roivant Sciences to purchase shares; expected close Dec 12, 2025.
Potentially registrational D2T RA trial of IMVT-1402: top-line results now expected in 2026 (previously initial open-label only in 2026).
Batoclimab Phase 3 TED studies: top-line results delayed to H1 2026 (previously by end of 2025); results shared concurrently.
Discussions commenced with HanAll to potentially return batoclimab rights; may result in dispute or arbitration.
Existing cash plus offering proceeds expected to fund operations through potential commercial launch of IMVT-1402 in Graves' Disease.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.